Pfizer announced the end of development of its experimental weight loss pill after a patient experienced liver injury that was potentially caused by the pill in a clinical trial. The obesity related treatment called danuglipron was aimed to compete in the weight-loss market. Pfizer had earlier scrapped another of its oral obesity drugs due to liver issues found in trial.